Literature DB >> 18090045

Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.

Grace A Lee1, Madhu Rao, Kathleen Mulligan, Joan C Lo, Francesca Aweeka, Jean-Marc Schwarz, Morris Schambelan, Carl Grunfeld.   

Abstract

BACKGROUND: Some HIV protease inhibitors (PIs) have been shown to induce insulin resistance in vitro but the degree to which specific PIs affect insulin sensitivity in humans is less well understood.
METHODS: In two separate double-blind, randomized, cross-over studies, we assessed the effects of a single dose of ritonavir (800 mg) and amprenavir (1200 mg) on insulin sensitivity (euglycemic hyperglycemic clamp) in healthy normal volunteers.
RESULTS: Ritonavir decreased insulin sensitivity (-15%; P = 0.008 versus placebo) and non-oxidative glucose disposal (-30%; P = 0.0004), whereas neither were affected by amprenavir administration.
CONCLUSION: Compared to previously performed studies of identical design using single doses of indinavir and lopinavir/ritonavir, a hierarchy of insulin resistance was observed with the greatest effect seen with indinavir followed by ritonavir and lopinavir/ritonavir, with little effect of amprenavir.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18090045      PMCID: PMC3167072          DOI: 10.1097/QAD.0b013e32826fbc54

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Authors:  K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

2.  Protease inhibitor-associated hyperglycaemia.

Authors:  M P Dubé; D L Johnson; J S Currier; J M Leedom
Journal:  Lancet       Date:  1997-09-06       Impact factor: 79.321

3.  Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.

Authors:  Grace A Lee; Joan C Lo; Francesca Aweeka; Jean-Marc Schwarz; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Journal:  Clin Infect Dis       Date:  2006-07-26       Impact factor: 9.079

4.  Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.

Authors:  Qingyun Yan; Paul W Hruz
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-01       Impact factor: 3.731

5.  Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.

Authors:  B M Sadler; P J Piliero; S L Preston; P P Lloyd; Y Lou; D S Stein
Journal:  AIDS       Date:  2001-05-25       Impact factor: 4.177

6.  Metabolic effects of indinavir in healthy HIV-seronegative men.

Authors:  M A Noor; J C Lo; K Mulligan; J M Schwarz; R A Halvorsen; M Schambelan; C Grunfeld
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

Review 7.  Clinical pharmacology and pharmacokinetics of amprenavir.

Authors:  Brian M Sadler; Daniel S Stein
Journal:  Ann Pharmacother       Date:  2002-01       Impact factor: 3.154

8.  Indinavir increases glucose production in healthy HIV-negative men.

Authors:  Jean-Marc Schwarz; Grace A Lee; Seongsoo Park; Mustafa A Noor; Jeongae Lee; Michael Wen; Joan C Lo; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Journal:  AIDS       Date:  2004-09-03       Impact factor: 4.177

9.  Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Authors:  R A DeFronzo; J D Tobin; R Andres
Journal:  Am J Physiol       Date:  1979-09

Review 10.  Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.

Authors:  A Hsu; G R Granneman; R J Bertz
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

View more
  20 in total

1.  Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.

Authors:  Risheng Cao; Yiqiao Hu; Yun Wang; Emily C Gurley; Elaine J Studer; Xuan Wang; Phillip B Hylemon; William M Pandak; Arun J Sanyal; Luyong Zhang; Huiping Zhou
Journal:  J Pharmacol Exp Ther       Date:  2010-05-14       Impact factor: 4.030

2.  Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.

Authors:  Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

3.  GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.

Authors:  Paul W Hruz; Qingyun Yan; Luong Tsai; Joseph Koster; Lianhong Xu; Tomas Cihlar; Christian Callebaut
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

4.  Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.

Authors:  Steven A Taylor; Grace A Lee; Vivian Y Pao; Jayaranjan Anthonypillai; Francesca T Aweeka; Jean-Marc Schwarz; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2010-11       Impact factor: 3.731

5.  Brachial and central blood pressure in HIV-infected subjects.

Authors:  Alessandro Maloberti; Dario Dozio; Mauro Betelli; Alessandra Bandera; Nicola Squillace; Andrea Gori; Giovanna Castoldi; Andrea Stella; Giuseppe Mancia; Cristina Giannattasio
Journal:  Hypertens Res       Date:  2015-03-05       Impact factor: 3.872

Review 6.  Antiretroviral therapy in the clinic.

Authors:  Athe M N Tsibris; Martin S Hirsch
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

7.  Association of antiretroviral therapy with fibrinogen levels in HIV-infection.

Authors:  Erin Madden; Grace Lee; Donald P Kotler; Christine Wanke; Cora E Lewis; Russell Tracy; Steven Heymsfield; Michael G Shlipak; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

8.  Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.

Authors:  Grace M Aldrovandi; Jane C Lindsey; Denise L Jacobson; Amanda Zadzilka; Elizabeth Sheeran; Jack Moye; Peggy Borum; William A Meyer; Dana S Hardin; Kathleen Mulligan
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

9.  Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.

Authors:  Wen Guo; Siu Wong; Jeffrey Pudney; Ravi Jasuja; Ning Hua; Lan Jiang; Andrew Miller; Paul W Hruz; James A Hamilton; Shalender Bhasin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-17       Impact factor: 8.311

10.  HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.

Authors:  Paul W Hruz
Journal:  Curr Opin HIV AIDS       Date:  2008-11       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.